Candel Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
During thethree months ended September 30, 2025, none of our directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934, as amended)adopted, terminated ormodified a Rule 10b5-1 trading arrangement or any “non-Rule 10b5-1 trading agreement” (as defined in Item 408(c) of Regulation S-K), except as set forth below:
| Name and Position | Type of Plan | Action Taken | Date Adopted | Date Terminated | Maximum Number of Securities to Be Sold |
|---|---|---|---|---|---|
| W. Garrett Nichols, M.D., M.S. (Chief Medical Officer) | Rule 10b5-1 trading arrangement (1) | Termination | November 22, 2024 | August 15, 2025 | 49,847 |
(1) Intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c).
(2) As of the date of termination of such Rule 10b5-1 trading arrangement, Dr. Nichols sold 47,034 shares of our common stock pursuant to the terms of such trading plan
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.